Free Trial

ALT5 Sigma (ALTS) Competitors

ALT5 Sigma logo
$7.10 -0.19 (-2.61%)
Closing price 07/24/2025 04:00 PM Eastern
Extended Trading
$7.35 +0.25 (+3.52%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ALTS vs. ATYR, SLDB, TERN, SIGA, PRTC, TRML, RZLT, KMDA, CGEM, and RGNX

Should you be buying ALT5 Sigma stock or one of its competitors? The main competitors of ALT5 Sigma include aTyr Pharma (ATYR), Solid Biosciences (SLDB), Terns Pharmaceuticals (TERN), Siga Technologies (SIGA), PureTech Health (PRTC), Tourmaline Bio (TRML), Rezolute (RZLT), Kamada (KMDA), Cullinan Therapeutics (CGEM), and REGENXBIO (RGNX). These companies are all part of the "pharmaceutical products" industry.

ALT5 Sigma vs. Its Competitors

ALT5 Sigma (NASDAQ:ALTS) and aTyr Pharma (NASDAQ:ATYR) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

ALT5 Sigma has higher revenue and earnings than aTyr Pharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ALT5 Sigma$18.05M6.87-$6.24MN/AN/A
aTyr Pharma$230K2,147.61-$64.02M-$0.81-6.85

aTyr Pharma has a consensus target price of $20.20, indicating a potential upside of 263.96%. Given aTyr Pharma's stronger consensus rating and higher possible upside, analysts clearly believe aTyr Pharma is more favorable than ALT5 Sigma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ALT5 Sigma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
aTyr Pharma
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14

In the previous week, aTyr Pharma had 6 more articles in the media than ALT5 Sigma. MarketBeat recorded 8 mentions for aTyr Pharma and 2 mentions for ALT5 Sigma. ALT5 Sigma's average media sentiment score of 0.63 beat aTyr Pharma's score of 0.59 indicating that ALT5 Sigma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ALT5 Sigma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
aTyr Pharma
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ALT5 Sigma has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.

6.3% of ALT5 Sigma shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 4.9% of ALT5 Sigma shares are held by insiders. Comparatively, 3.7% of aTyr Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

aTyr Pharma has a net margin of 0.00% compared to ALT5 Sigma's net margin of -38.58%. aTyr Pharma's return on equity of -87.09% beat ALT5 Sigma's return on equity.

Company Net Margins Return on Equity Return on Assets
ALT5 Sigma-38.58% -113.79% -8.96%
aTyr Pharma N/A -87.09%-64.77%

Summary

aTyr Pharma beats ALT5 Sigma on 9 of the 15 factors compared between the two stocks.

Get ALT5 Sigma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALTS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALTS vs. The Competition

MetricALT5 SigmaFIN IndustryFinance SectorNASDAQ Exchange
Market Cap$127.25M$8.01B$12.31B$9.47B
Dividend YieldN/A4.68%5.53%3.99%
P/E RatioN/A19.0119.0619.95
Price / Sales6.875.8626.22100.93
Price / CashN/A21.8321.8458.97
Price / Book14.492.792.275.90
Net Income-$6.24M$314.15M$998.01M$258.42M
7 Day Performance-3.01%3.17%0.88%2.11%
1 Month Performance-24.31%19.31%4.39%12.44%
1 Year Performance255.00%26.66%540.85%19.55%

ALT5 Sigma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALTS
ALT5 Sigma
0.1425 of 5 stars
$7.10
-2.6%
N/A+262.2%$127.25M$18.05M0.00170
ATYR
aTyr Pharma
2.3002 of 5 stars
$5.24
-8.2%
$20.20
+285.5%
+187.6%$508.21M$230K-6.4753High Trading Volume
SLDB
Solid Biosciences
3.2936 of 5 stars
$6.23
-2.2%
$15.10
+142.4%
-24.4%$493.77M$8.09M-2.08100
TERN
Terns Pharmaceuticals
3.6241 of 5 stars
$6.00
+6.4%
$15.63
+160.4%
-30.1%$492.58MN/A-5.5040Positive News
SIGA
Siga Technologies
2.1158 of 5 stars
$6.85
flat
N/A-27.4%$489.37M$138.72M10.2240News Coverage
Upcoming Earnings
Options Volume
PRTC
PureTech Health
2.6479 of 5 stars
$18.23
-7.3%
$45.00
+146.9%
-16.2%$472.52M$4.83M0.00100Positive News
Upcoming Earnings
TRML
Tourmaline Bio
2.1561 of 5 stars
$18.86
+3.5%
$49.33
+161.6%
+13.8%$468.24MN/A-5.8844Positive News
RZLT
Rezolute
2.6388 of 5 stars
$5.37
-0.2%
$11.83
+120.4%
+26.5%$468.04MN/A-4.6740
KMDA
Kamada
3.326 of 5 stars
$7.64
-2.1%
$13.00
+70.2%
+33.7%$448.54M$160.95M26.34360
CGEM
Cullinan Therapeutics
1.4507 of 5 stars
$8.11
+7.8%
$30.00
+269.9%
-59.0%$443.79MN/A-2.7930Positive News
RGNX
REGENXBIO
4.2711 of 5 stars
$8.57
+0.9%
$31.63
+269.0%
-33.1%$425.86M$83.33M-2.76370News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:ALTS) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners